Oklo’s (OKLO) shares dropped roughly 5% on Wednesday, extending their after-hours drop the previous day. This follows the nuclear startup’s Q1 2026 net loss, which matched analysts’ estimates but deepened compared to a year ago.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
In response, analysts continue to issue bullish calls on the company. For instance, H.C. Wainwright analyst Sameer Joshi reaffirmed both his Buy rating on OKLO and his $90 per share price target, which implies about 29% upside in the months ahead.
Why H.C. Wainwright Still Backs Oklo
Defending his rating, Joshi noted that Oklo did not report any commercial revenue, as expected — as its products are still in the development stage — but pointed out that the small modular reactor (SMR) producer cut down its operating expenses by 10% to $51.5 million compared to the prior quarter. The analyst also noted that Oklo ended the quarter with no debt and $2.5 billion in cash.
The H.C. Wainwright researcher also sees upside in Oklo’s partnership with the Battelle Energy Alliance, the consortium that runs the U.S. Department of Energy’s Idaho National Laboratory. Oklo’s tie-up is to use AI technologies to boost the design process for its advanced reactor and fuel systems.
Joshi also pointed to Oklo’s management update on progress in efforts toward achieving criticality at the Groves Test Reactor. This means getting the pilot nuclear test reactor in Texas to sustain a controlled nuclear chain reaction — a milestone key to validating Oklo’s technology.
William Blair Defends Buy Rating on Oklo
Similarly, William Blair’s five-star analyst Jed Dorsheimer maintained his Buy rating on OKLO but did not set a price target. Dorsheimer pointed to several factors for the rating, including significant progress across Oklo’s power, fuel, and isotope business segments.
The latter refers to Oklo’s business of selling special radioactive materials (isotopes) for purposes such as medical diagnostics and treatment.
Is Oklo a Good Stock to Buy?
Across Wall Street, Oklo’s shares continue to carry a Moderate Buy consensus rating from analysts. This is based on 10 Buys and six Holds assigned over the past three months.
However, the average OKLO price target of $89.82 implies roughly 28% upside.
